20-F: Basel Medical Group Reports Significant FY2025 Loss Amidst Goodwill Impairment and Auditor Concerns

Basel Medical Group Ltd. reported a substantial net loss for the fiscal year ended June 30, 2025, primarily driven by a significant goodwill impairment, alongside an auditor's disclaimer of opinion and identified material weaknesses in internal controls.

Summary

• Basel Medical Group Ltd. reported a net loss of S$12,088,104 (US$9,503,974) for the fiscal year ended June 30, 2025, a significant decline from a profit of S$2,072,800 in FY2024.
• Revenue increased by 12.6% to S$11,319,944 (US$8,900,027) in FY2025, primarily due to the acquisition of the Bethesda group of general practitioner clinics, which contributed S$895,362.
• A substantial impairment loss on goodwill of S$11,145,691 (US$8,763,025) was recognized in FY2025, attributed to the newly acquired Bethesda group's operations not yet being turned around.
• The independent registered public accounting firm issued a disclaimer of opinion on the financial statements for FY2025 due to insufficient supporting documentation and pending finalization of the Purchase Price Allocation (PPA) for the Bethesda acquisition, as well as inability to evaluate goodwill impairment assumptions.
• Management identified a material weakness in internal control over financial reporting related to a lack of adequately skilled staff possessing IFRS knowledge for financial reporting purposes.
• Employee benefit expenses increased by 75.8% to S$6,397,933 (US$5,030,217) in FY2025, mainly due to increased headcount and bonus payments, including staff from the Bethesda group.
• The company successfully listed on NASDAQ in February 2025, issuing 2,205,000 ordinary shares at US$4.00 per share, with an additional 330,750 shares from an overallotment option in March 2025, bringing total outstanding shares to 18,785,750.
• Net cash used in operating activities amounted to S$4,344,125 (US$3,415,460) in FY2025, compared to S$2,509,285 generated in FY2024.
• Net cash used in investing activities was S$11,040,944 (US$8,680,671) in FY2025, largely due to the acquisition of the new subsidiary.
• Net cash generated from financing activities was S$16,908,838 (US$13,294,157) in FY2025, driven by share issuance proceeds and a decrease in amounts due from related parties.
• The company operates 8 medical clinics in Singapore, offering orthopedic, trauma, sports medicine, neurosurgical, general practice, health screening, mental health, and women's health services.
• Rainforest Capital VCC, the controlling shareholder, owns 54.3% of the ordinary shares as of November 17, 2025.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to a significant net loss, a substantial goodwill impairment, an auditor's disclaimer of opinion on the financial statements, and identified material weaknesses in internal controls. While revenue increased, the underlying profitability and financial reporting integrity are severely impacted, overshadowing any positive operational developments.

Positives

• Overall revenue increased by 12.6% to S$11,319,944 (US$8,900,027) in FY2025.
• Revenue from orthopedic specialist clinics at Gleneagles increased by 3.7% to S$10,424,582 (US$8,196,071) in FY2025.
• Higher patient count from corporate clients for specialist clinics, with revenue increasing by S$464,885 in FY2025, attributed to the rebound of the construction sector post-COVID.
• Successful NASDAQ listing in February 2025, raising approximately US$7,246,609 in net proceeds.
• Expansion of services through the acquisition of Bethesda Medical Pte. Ltd., adding six general practice clinics in Singapore.
• The company has a dedicated corporate marketing team and engages in various marketing activities including personal referrals, advertising, social media, insurance panels, and participation in medical conferences.
• Management believes working capital is sufficient for at least 12 months after the period end, considering cash flows, external borrowings, and existing cash.
• Rainforest Capital VCC, the major shareholder, has agreed to provide financial support for at least 12 months from the auditor's report date.

Negatives

• Reported a significant net loss of S$12,088,104 (US$9,503,974) for FY2025, a substantial decrease from a profit in FY2024.
• Incurred a large impairment loss on goodwill of S$11,145,691 (US$8,763,025) related to the Bethesda group acquisition, indicating underperformance of the acquired entity.
• The independent registered public accounting firm issued a disclaimer of opinion on the financial statements for FY2025 due to insufficient audit evidence regarding the Bethesda acquisition and goodwill impairment.
• Identified a material weakness in internal control over financial reporting due to a lack of adequately skilled staff with IFRS knowledge.
• Employee benefit expenses increased significantly by 75.8% to S$6,397,933 (US$5,030,217) in FY2025.
• Depreciation expense increased by 123.4% to S$1,181,128 (US$928,633) in FY2025.
• Other operating expenses increased by 120.3% to S$3,331,619 (US$2,619,403) in FY2025, partly due to exchange loss and professional fees.
• Revenue from individual walk-in patients for specialist clinics decreased by S$91,225 in FY2025.
• The formal Purchase Price Allocation (PPA) for the Bethesda acquisition is still pending finalization by April 30, 2026, creating uncertainty in asset and liability valuations.

Risks

• Dependence on key medical practitioners, with potential adverse effects if services are lost or replacements are not timely.
• Competition from other similar healthcare service providers in private and government-owned hospitals, medical centers, and clinics, potentially leading to lower profit margins and loss of market share.
• Reliance on brand names, trademarks, and the reputation of specialist doctors, with risks of brand dilution or damage from negative publicity or legal actions.
• Dependence on the continuing operations of private hospitals and medical centers where clinics are located, making the business vulnerable to disruptions at these facilities.
• Dependence on key relationships with corporations for a significant portion of patient volume, with risks of termination or reduced demand.
• Increase in operating costs, particularly lease rental rates, and the risk of relocation, which could disrupt business operations and affect profits.
• Exposure to credit risks of customers, especially corporate clients, with potential for delays in payment or uncollectible trade receivables.
• Limited control over suppliers and the quality of products they provide, potentially leading to defects, product recalls, or reputational damage.
• Impact of technological disruptions in the healthcare sector, such as telemedicine, which could reduce demand for in-clinic services and increase competitive pricing pressures.
• Potential negative impact from technological advancements, failures, and other challenges associated with medical equipment and information technology systems.
• Risks associated with cybersecurity and the handling of personal information and medical data, including unauthorized disclosure, data breaches, and non-compliance with privacy laws.
• Failure to safeguard intellectual property rights or any infringement of third-party rights, which could have detrimental effects on the business.
• Failure to comply with restrictions in bank loans, potentially resulting in an event of default and adverse effects on financial condition.
• Risk of significant product liability lawsuits affecting financial performance and reputation.
• Decline in demand for private healthcare services due to economic slowdowns or increased preference for subsidized public healthcare.
• Adverse effects from the spread or outbreak of contagious or virulent diseases, potentially leading to temporary clinic closures or reduced patient volume.
• Exposure to medical and legal claims, regulatory actions, and professional liability arising from clinical and specialist services.
• Inadequate insurance coverage for potential liability risks, despite mandatory professional malpractice insurance.
• Compliance costs and risks associated with regulations and licensing conditions governing the healthcare sector, including potential non-retention or non-renewal of necessary licenses.
• Adverse effects from the regulation of healthcare fees and the potential rise in the number of medical practitioners, leading to pressure on service rates.
• Challenges faced by the broader healthcare industry, including rising costs of medicines, stricter laws on patient information, and global events affecting medical travel.
• Exposure to political, economic, and social developments, as well as laws, regulations, and licensing requirements in Singapore.
• Additional costs incurred as a public company, negatively impacting net income and liquidity.
• Disadvantage to competitors that are private companies due to public disclosure obligations.
• Exemption from certain provisions applicable to U.S. domestic public companies as a foreign private issuer, potentially providing less information to investors.
• Reliance on exemptions from certain corporate governance requirements as a controlled company under Nasdaq rules, potentially affording less protection to shareholders.
• Uncertainty if reduced reporting requirements applicable to emerging growth companies will make ordinary shares less attractive to investors.
• Volatility or decline in the market price of ordinary shares regardless of operating performance.
• Potential decline in market price due to any resale of ordinary shares in the public market.
• Future issuances or sales, or perceived issuances or sales, of substantial amounts of ordinary shares could materially and adversely affect the prevailing market price and ability to raise capital.
• Future financing may cause dilution in shareholding or place restrictions on operations.
• Controlling shareholder (Rainforest Capital VCC) holds control, limiting other shareholders' ability to influence decisions.
• Lack of an active, liquid trading market for ordinary shares.
• Immediate and substantial dilution for investors purchasing ordinary shares in the offering.
• Ineffective internal controls over financial reporting and inability of independent registered public accounting firm to certify effectiveness.
• Less protection for member rights under BVI law compared to U.S. law.
• Reliance on price appreciation of ordinary shares for return on investment, as no dividends are expected in the near future.
• Increased costs and risk of non-compliance due to changing laws and regulations regarding regulatory matters, corporate governance, and public disclosure.
• Additional costs and procedural obstacles in enforcing foreign judgments or bringing actions in the British Virgin Islands or Singapore based on U.S. or other foreign laws.
• Rapid and substantial volatility in the price of ordinary shares, potentially unrelated to operating performance.
• Risk of securities litigation, which is expensive and could divert management attention.
• Decline in market price or trading volume if securities or industry analysts do not publish research reports or issue adverse recommendations.
• Risk of delisting from the Nasdaq Capital Market if listing requirements are not satisfied.
• Anti-takeover provisions in the memorandum and articles of association may discourage, delay, or prevent a change in control.
• Inability to present proposals before annual general meetings or extraordinary general meetings not called by shareholders.

Future Outlook

The company aims to continue expanding its operations in Singapore to include general practices and other specialized practices, with a vision to grow into a more international medical group and become the premier healthcare provider in Southeast Asia, offering seamless, one-stop solutions. Management intends to retain most, if not all, available funds and future earnings to fund business development and growth, and does not expect to pay any cash dividends in the near future. Measures are planned to improve internal control over financial reporting, including hiring additional accounting personnel and establishing a financial and system control framework, along with regular IFRS and SEC financial reporting training. Post-reporting period events indicate further investments in new specialist and imaging clinics and securing a new term loan facility.

Management Comments

• Dr. Darren Chhoa, Group Chief Executive Officer, leads the Group's health value proposition strategy, focusing on expansion, introduction of latest clinical solutions, and developing partnerships.
• Ms. Jianing Lu, Director and Chief Financial Officer, leads the Group's accounting, finance, reporting, and budgetary functions.
• Mr. Tan Boon Chye (Darren) joined as Group Chief Commercial Officer in August 2025.
• Management is of the reasonable opinion that, after taking into consideration cash flows, external borrowings, and existing cash, the working capital available is sufficient to meet present requirements for at least 12 months.
• Management concluded that disclosure controls and procedures as of June 30, 2025, were not effective.
• Management identified a significant weakness in internal control over financial reporting associated with a lack of adequately skilled staff possessing IFRS knowledge.

Industry Context

The company operates in Singapore's highly fragmented orthopedic treatment market, characterized by low barriers to entry and low consolidation. Competition is faced from both medical practitioners (orthopedics, neurosurgeons, neurologists, rheumatologists) and non-medical practitioners (traditional Chinese medicine, physiotherapists, chiropractors). The general practice clinic segment also faces intense competition from numerous solo and group practices across Singapore. The industry is influenced by technological disruptions like telemedicine, which offer alternative access to medical services and medicine, potentially reducing demand for in-clinic visits and increasing pricing pressures. Regulatory factors, such as the Singapore Ministry of Health's Fee Benchmarks for private sector professional fees and the increasing number of medical practitioners, are expected to exert pressure on service rates. The rebound of the construction sector post-COVID has led to an increase in injury-related cases, benefiting the company's specialist orthopedic services.

Comparison to Industry Standards

• The company's fee scale is determined and periodically revised with reference to the Singapore Ministry of Health's Fee Benchmarks, which are recommended charges for doctors and hospital fees in the private sector.
• The company's practices regarding foreign private issuer exemptions and controlled company status align with Nasdaq rules for such entities, but may differ from corporate governance standards applicable to U.S. domestic issuers, potentially offering less protection to shareholders.
• The company's internal control over financial reporting was deemed not effective, and a material weakness was identified, which is below industry best practices for public companies, especially given the auditor's disclaimer of opinion.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of this annual report, the company is not a party to, nor aware of, any legal proceeding, investigation, or claim likely to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Loan to related party (Bethesda group) of S$450,000 (US$354,372) in FY2025.
• Interest income on loan to related party of S$1,917 (US$1,507) in FY2025.
• Payment made on behalf of related party of S$10,000 (US$7,862) in FY2025.
• Management fee of S$4,900,000 (US$3,852,504) incurred between the Singapore holding company and its subsidiary within the group in FY2025.
• Rainforest Capital VCC assumed and fully settled S$11,877,624 (US$8,783,276) in outstanding receivables due from Dr. Kevin Yip (former director) and Singmed Investment Pte Ltd by September 23, 2024.
• Amount due to related parties (shareholders and directors) of S$1,642,599 (US$1,291,453) as of June 30, 2025, which are non-trade, unsecured, interest-bearing, and repayable on demand.
• Compensation of key management personnel (salaries, bonuses, CPF) totaled S$752,194 (US$591,394) in FY2025 and S$121,337 in FY2024.

Stakeholder Impact

• Shareholders: Experience significant dilution from the IPO, face a substantial net loss for FY2025, and are not expected to receive dividends in the near future, relying solely on price appreciation. Less protection for member rights due to BVI law and foreign private issuer/controlled company status. Potential for stock price volatility and delisting risk.
• Employees: Increased headcount and higher employee benefit expenses, indicating growth in the workforce. Training programs are in place to ensure competence and quality of service.
• Customers/Patients: Benefit from the expansion of services (general practice, new specialist clinics) and the company's focus on quality control and advanced medical technology. Potential impact from competition and regulation of healthcare fees.
• Suppliers: The company relies on external suppliers for devices, equipment, and medication, with limited control over quality, posing a risk if products are defective.
• Creditors: The company has bank loans and lease liabilities, with past defaults on loan terms. Compliance with restrictions is crucial to avoid events of default that could materially adversely affect the business.

Next Steps

• Complete the formal Purchase Price Allocation (PPA) exercise for the Bethesda group acquisition by April 30, 2026.
• Implement measures to improve internal control over financial reporting, including hiring additional accounting personnel.
• Establish a financial and system control framework.
• Initiate regular IFRS and SEC financial reporting training programs for accounting and financial personnel.
• Continue expansion in Singapore to general practices and other specialized practices.
• Expand into other Southeast Asian countries.
• Develop new orthopedic specialist clinics at Farrer Park, Novena, and Orchard.
• Establish a new eye specialist clinic (Eyetrust Medical Pte Ltd).
• Establish a new imaging center (Chartered Imaging Pte Ltd).
• Manage the S$3,000,000 term loan facility obtained in October 2025.

Key Dates

Recommendation

The filing reveals a deeply concerning financial picture, marked by a substantial net loss of over S$12 million for FY2025, primarily due to an S$11 million goodwill impairment on a newly acquired entity. This indicates significant overvaluation or underperformance of the acquisition. Compounding this, the independent auditor issued a disclaimer of opinion, signifying a fundamental inability to form an opinion on the financial statements' fairness, which is a severe red flag for investors. Furthermore, management identified a material weakness in internal controls over financial reporting, suggesting unreliable financial data. While revenue increased, the underlying profitability, financial integrity, and control environment are severely compromised. These factors collectively point to extreme risk and a lack of transparency, making the stock highly unattractive for investment. A 'strong sell' is warranted given the confluence of these critical negative indicators.

Keywords

Orthopedic, Neurosurgery, Healthcare, Singapore, Medical Clinics, SEC Filing, 20-F, Financial Results, Goodwill Impairment, Internal Controls, NASDAQ, Public Company, Financial Loss, Acquisition, Bethesda Medical, Rainforest Capital VCC, Corporate Governance, Risk Factors, Medical Services, Physiotherapy, Health Screening, Emerging Growth Company, Foreign Private Issuer